Systemic therapies for inflammatory eye disease: past, present and future

Area of Science:

• Ophthalmology
• Immunology

Background:

• Inflammatory eye diseases, particularly uveitis, face significant treatment development challenges.
• Historically, progress has been limited by small patient populations, disease heterogeneity, and diagnostic inconsistencies.

Purpose of the Study:

• To review the evidence base for inflammatory eye disease treatments from a historical perspective.
• To identify and discuss strategies for overcoming traditional hurdles in developing ocular inflammation therapies.

Main Methods:

• Literature review focusing on historical treatment evidence for inflammatory eye disease.
• Analysis of challenges including small patient cohorts, disease heterogeneity, and outcome measure limitations.
• Exploration of strategies from other medical fields to advance ocular inflammation treatment development.

Main Results:

• Identified key challenges: small populations, heterogeneous groups, poor phenotyping, diagnostic issues, subjective outcomes, and low commercial interest.
• Highlighted successful strategies from other specialties: clinical trial cultures, public-private partnerships, advanced drug design, and personalized medicine via biomarkers.
• Emphasized the potential for applying these advances to improve treatments for ocular inflammation.

Conclusions:

• Despite challenges, there are significant opportunities to improve treatments for inflammatory eye disease.
• Adopting strategies from other fields, such as biomarker-defined protocols and advanced drug design, holds promise for developing safer and more effective therapies.
• Personalized medicine approaches are crucial for advancing the treatment landscape of ocular inflammation.